Registry of Lobbyists
Version 6 of 6 (2002-04-02 to 2003-01-24) was submitted prior to the Lobbying Act coming into force on July 2, 2008. Due to different information requirements at that time, the registration is presented in the following format.
| Corporation: |
AVENTIS PASTEUR
CONNAUGHT CAMPUS, 1755 STEELES AVE WEST TORONTO, ON M2R 3T4 Canada |
| Telephone number: | 416-667-2694 |
| Fax number: | 416-667-2865 |
| Responsible officer name and position during the period of this registration: | DONALD S MCKIBBIN, DIRECTOR, PUBLIC & INDUSTRY RELATIONS |
| Description of activities: | AVENTIS PASTEUR IS THE WORLD'S LEADING PRODUCER OF VACCINES FOR HUMAN HEALTH AND A MEMBER OF THE AVENTIS FAMILY OF COMPANIES. AVENTIS PASTEUR'S CANADIAN OPERATION IN TORONTO PRODUCES VACCINES AND IMMUNOTHERAPEUTIC PRODUCTS. AVENTIS PASTEUR IN CANADA IS ALSO ONE OF THE MOST RESEARCH INTENSIVE BIOTECHNOLOGY COMPANIES IN THIS COUNTRY SPENDING 40 CENTS OF EVERY DOLLAR OF SALES REVENUE ON CANADIAN RESEARCH & DEVELOPMENT. RESEARCH PROJECTS CURRENTLY UNDERWAY INCLUDE:IMPROVED, ACELLULAR VACCINE AGAINST PERTUSSIS (WHOOPING COUGH)POTENTIAL NEW VACCINE AGAINST THE RESPIRATORY SYNCITIAL VIRUS (CROUP) FOR THE ELDERLY.NEW COMBINED VACCINES THAT PROTECT AGAINST MANY DISEASES WITH ONE INJECTIONA MAJOR RESEARCH PRIORITY IS THE DEVELOPMENT OF VACCINES AGAINST PATHOGENS RESPONSIBLE FOR HUMAN CANCERS. THIS PROGRAM INVOLVES MULTIPLE CANADIAN PARTNERS AND COULD REACH $360 MILLION OVER 10 YEARS.AVENTIS PASTEUR IS PART OF AVENTIS S.A. ONE OF THE WORLD'S LARGEST LIFE SCIENCES COMPANIES. |
| The client is a subsidiary of the following parent companies: |
AVENTIS S.A.
STRASBOURG France |
| Coalition | The corporation is not a member of a coalition. |
| Subsidiary: | The corporation does not have any subsidiaries that could be affected by the outcome of the undertaking. |
| Other direct interests | The corporation's activities are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking. |
| Was the corporation funded in whole or in part by any domestic or foreign government institution in the last completed financial year? | No |
| Federal departments or organizations which have been or will be communicated with during the course of the undertaking: | Canadian International Development Agency (CIDA), Competition Tribunal (CT), Foreign Affairs and International Trade Canada (DFAITC), Health Canada (HC), Industry Canada, INVESTMENT REVIEW AGENCY, National Research Council (NRC), Patented Medicine Prices Review Board (PMPRB) |
|
Communication techniques that have been used or are expected to be used in the course of the undertaking:
|
Informal communications, Meetings, Telephone calls, Written communications, whether in hard copy or electronic format |
| Subject Matter: Areas of Concern: | Consumer Issues, Education, Government Procurement, Health, Industry, Intellectual Property, Internal Trade, International Trade, Science and Technology |
| Subject Matter: Particulars: | ANY FURTHER REVIEW OF DRUG PATENT LEGISLATION ( FORMERLY BILL C-91);TECHNOLOGY PARTNERSHIPS CANADA PROGRAM;BIOTECHNOLOGY - VACCINE MANUFACTURING;SCIENTIFIC EDUCATION; STUDENT BIOTECHNOLOGY PROGRAMS; HUMAN RESOURCES. |